Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients
- PMID: 16362296
- DOI: 10.1007/s00280-005-0160-y
Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients
Abstract
Introduction: Plasma protein binding is an important factor for many drugs that can influence the tissue distribution and pharmacokinetics. alpha(1)-acid glycoprotein (AGP) is an acute-phase protein that can increase in plasma of patients with several pathological conditions including cancer. Studies performed in cultured cells indicate that paclitaxel cytotoxicity is reduced by adding AGP and the sensitivity to paclitaxel is restored by displacing its binding to AGP with clindamycin, resulting in an increased paclitaxel cell uptake. The purpose of this study was to evaluate whether clindamycin modifies paclitaxel pharmacokinetics also in cancer patients.
Patients and methods: Sixteen patients with advanced ovarian cancer, previously treated with surgery and chemotherapy were enrolled in this study. A pharmacokinetic study of paclitaxel was performed in the first three cycles of the consolidation therapy (paclitaxel and carboplatin) in each patient. In these cycles paclitaxel was administered alone and with two different doses (600 and 1,200 mg) of concurrent clindamycin. The sequence of the three treatments was randomly assigned in each patient in order to avoid the same order of treatments.
Results: Paclitaxel pharmacokinetics were partly modified by the concurrent administration of clindamycin. C (max) and AUC(0-last) of paclitaxel were significantly higher when the drug was given alone than when it was coadministered with 1,200 mg clindamycin. Moreover, AGP concentrations seem to have a small but statistically significant influence on paclitaxel pharmacokinetic, since AUC(0-last) showed a positive significant correlation with AGP plasma concentration when paclitaxel was given alone. The linear relation was lost when paclitaxel was coadministered with 1,200 mg clindamycin. Toxicity was not influenced by the coadministration of clindamycin.
Conclusion: The hypothesis that clindamycin could affect paclitaxel pharmacokinetics seems to be verified with this study. Nevertheless, changes induced by giving the combination of the two drugs are minimal and thus of questionable clinical relevance.
Similar articles
-
Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels.Eur J Cancer. 2010 Feb;46(3):505-16. doi: 10.1016/j.ejca.2009.11.006. Epub 2009 Dec 16. Eur J Cancer. 2010. PMID: 20007015 Clinical Trial.
-
Nonlinear pharmacokinetics of paclitaxel in ovarian cancer patients.Acta Pharmacol Sin. 2000 Jul;21(7):596-9. Acta Pharmacol Sin. 2000. PMID: 11360664
-
A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.Crit Rev Oncol Hematol. 2008 Jun;66(3):229-36. doi: 10.1016/j.critrevonc.2007.12.005. Epub 2008 Feb 1. Crit Rev Oncol Hematol. 2008. PMID: 18243011 Clinical Trial.
-
Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.J Natl Compr Canc Netw. 2004 Sep;2 Suppl 2:S60-73. J Natl Compr Canc Netw. 2004. PMID: 19780247 Review.
-
Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane.J Control Release. 2005 Dec 5;109(1-3):120-6. doi: 10.1016/j.jconrel.2005.09.033. Epub 2005 Nov 16. J Control Release. 2005. PMID: 16297482 Review.
Cited by
-
High Penetration of Paclitaxel in Abdominal Wall of Rabbits after Hyperthermic Intraperitoneal Administration of Nab-Paclitaxel Compared to Standard Paclitaxel Formulation.Pharm Res. 2017 Jun;34(6):1180-1186. doi: 10.1007/s11095-017-2132-4. Epub 2017 Feb 28. Pharm Res. 2017. PMID: 28247168
-
Monitoring the Fate of Orally Administered PLGA Nanoformulation for Local Delivery of Therapeutic Drugs.Pharmaceutics. 2019 Dec 6;11(12):658. doi: 10.3390/pharmaceutics11120658. Pharmaceutics. 2019. PMID: 31817781 Free PMC article.
-
Bioreducible Hydrophobin-Stabilized Supraparticles for Selective Intracellular Release.ACS Nano. 2017 Sep 26;11(9):9413-9423. doi: 10.1021/acsnano.7b04979. Epub 2017 Aug 17. ACS Nano. 2017. PMID: 28806871 Free PMC article.
-
Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer.Br J Cancer. 2015 Jan 20;112(2):306-12. doi: 10.1038/bjc.2014.602. Epub 2014 Dec 2. Br J Cancer. 2015. PMID: 25461804 Free PMC article.
-
First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel.Int J Nanomedicine. 2014;9:209-21. doi: 10.2147/IJN.S41770. Epub 2013 Dec 24. Int J Nanomedicine. 2014. PMID: 24399877 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical